Portfolio Finder


miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic methods. The first product, based on the quantification of microRNA, is a blood test for the detection of testicular cancer. The high sensitivity and accuracy of the test improves the diagnosis and therapy of patients significantly and reduces the costs for the health care system. miRdetect has developed a patented platform technology, which allows the exact and reliable quantification of small amounts of genetic material in body fluids. This robust method represents the basis for the development of additional diagnostic tests.

Sector: In-Vitro Dx
HTGF-Manager: Dr. Angelika Vlachou
Added to portfolio 14. Dec 2018


In order to successfully treat the infected patient, you have to recognize and diagnose most reliably the infecting microbe.
Noscendo changes the way infection causative microbes are identified. Through a paradigm shift we introduce by using proprietary algorithms and software harnessing next generation sequencing, we identify pathogens from cell free nucleic acids in patient samples and thereby aid intensive care clinicians in their daily task to find the right decisions, enabling a targeted and successful treatment in an actionable timeframe.

Sector: In-Vitro Dx
Added to portfolio 27. Sep 2018


oncgnostics develops - based on proprietary epigenetic biomarkers - highly reliable molecular in-vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in oncology.

Sector: In-Vitro Dx
HTGF-Manager: Dr. Bernd Goergen
Added to portfolio 13. Mar 2012


Predemtec focuses on the research, development and manufacture of innovative diagnostic tests for use in the detection of dementia-related risk factors. The first product, the Predemtec DX test, is a serum-based immunoassay and uses analysis algorithms for the early detection and risk diagnosis of senile dementia (Alzheimer’s type, AD).

Sector: In-Vitro Dx
HTGF-Manager: Dr. Anke Caßing
Added to portfolio 27. May 2014